ASH 2025 – J&J’s multiple myeloma juggling act
Tecvayli plus Darzalex could challenge Carvykti in the push for a functional cure.
ASH 2025 – Adcetris good, follow-ons not so much
Pfizer reveals the discontinuation of PF-08046044.
ASH 2025 – Regeneron’s Lynozyfic shows front-line promise
Linker-MM4 data raise more questions about sequencing of therapies for multiple myeloma.
ASH 2025 – Gilead spills the beans on “fast” Car-T
It’s less about being fast, more about producing a better product.
NACLC 2025 – BioNTech gets a gotistobart boost
The first stage of Preserve-003 shows a survival benefit in post-PD-(L)1 lung cancer – with caveats.
ASH 2025 – BeOne assuages sonrotoclax safety concerns
Of 15 treatment-emergent adverse events, only one was deemed related to therapy.
ASH 2025 – BeOne pulls away from Nurix
On efficacy, at least, BeOne’s BTK degrader shows an edge.
ASH 2025 – Kura seeks further safety edge
The company will try to get the Komzifti QTc prolongation warning removed.
Crescent moves to close the bispecific gap
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
